BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 07, 2010
 |  BioCentury  |  Emerging Company Profile

LipimetiX: Aping APOE

LipimetiX developing peptides that mimic APOE's ability to clear cholesterol

LipimetiX LLC is hoping to bypass defective LDL receptors in the livers of patients with heritable hyperlipidemia with its mimetics of apolipoprotein E, a protein that can target two additional hepatic receptors capable of clearing LDL. The company is raising a $10-$15 million series A round to fund a Phase I/II trial it hopes to begin in 3Q11.

Patients with heritable hyperlipidemias, such as familial (type II) hypercholesterolemia, lack functional LDL receptors in the liver, which results in greatly decreased LDL clearance.

Drugs such as statins and bile acid sequestrants lead the liver to up-regulate expression of LDL receptors to clear more cholesterol from the blood. But these agents do not adequately control cholesterol because of the defective LDL receptors.

The addition of other lipid lowering agents, such as niacin, is often not enough for patients to reach target LDL levels.

Apolipoprotein E (APOE) binds to LDL and transports the triglyceride-rich molecules through the bloodstream to the liver. APOE is capable of targeting hepatic LDL receptors and two other receptors in the liver known as

Read the full 875 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >